TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05398081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefuroxime (Zinnat®)
Description: Antibiotic for prophylaxis against surgical site infection following craniotomy and laminectomy Here, Cefuroxime (Zinnat®), a second generation cephalosporin will be used

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone (Rocephin®)
Description: Antibiotic for prophylaxis against surgical site infection following craniotomy and laminectomy Here, Ceftriaxone (Rocephin®) a third generation cephalosporin will be used
Study: NCT06213675

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine rehabilitation treatment
Description: Routine rehabilitation treatment Includes oral rehabilitation, rehabilitation training for temporomandibular disorders, orthodontic treatment, and other physical therapy methods.which can alleviate symptoms by adjusting the bite, relaxing muscles, and increasing the range of motion of the temporomandibular joint.~Besides, it also Includes temporomandibular joint exercise training, relaxation training for facial muscles, and functional chewing training aimed at improving temporomandibular joint function and muscle balance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine rehabilitation treatment
Description: Routine rehabilitation treatment Includes oral rehabilitation, rehabilitation training for temporomandibular disorders, orthodontic treatment, and other physical therapy methods.which can alleviate symptoms by adjusting the bite, relaxing muscles, and increasing the range of motion of the temporomandibular joint.~Besides, it also Includes temporomandibular joint exercise training, relaxation training for facial muscles, and functional chewing training aimed at improving temporomandibular joint function and muscle balance.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-articular Injection
Description: The patient is positioned to maximize mouth opening, and a needle is inserted approximately 10-12 mm in front of the tragus after touching the ankle prominence. An 8# injection needle is chosen and inserted upward and slightly forward into the joint cavity. A total of 2 mL of lidocaine hydrochloride injection solution is injected, repeated once every 5 days for a total of 15 days.
Study: NCT06506071

Intervention type: DIAGNOSTIC_TEST
Intervention: Spectral CT
Description: Myocardial tissue characterization with Spectral CT

Intervention type: DIAGNOSTIC_TEST
Intervention: Spectral CT
Description: Myocardial tissue characterization with Spectral CT
Study: NCT05193227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST-01
Description: Administration of up to 8 mL ST-01 (70 mg/mL lidocaine)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control (Lidocaine Hydrochloride Injection USP Xylocaine® or Bupivacaine Hydrochloride Injection USP Marcaine®)
Description: Administration of up to 3 mg/kg bupivacaine hydrochloride injection (0.25%) or up to 4.5mg/kg lidocaine hydrochloride injection (0.5-1%)
Study: NCT06370078

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin Human
Description: To investigate the effect of early administration of albumin in the ICU after onset of septic shock compared to volume replacement therapy without albumin on patient outcome.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin Human
Description: To investigate the effect of early administration of albumin in the ICU after onset of septic shock compared to volume replacement therapy without albumin on patient outcome.
Study: NCT06436300

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational text messaging
Description: Intervention sends up to 4 motivational messages by text or email to Alaska Native men who are active patients and due for colorectal cancer screening. Incentive arms include promise of a $50 gift card or entry into a raffle for prize worth about $200 if they complete screening.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational text messaging
Description: Intervention sends up to 4 motivational messages by text or email to Alaska Native men who are active patients and due for colorectal cancer screening. Incentive arms include promise of a $50 gift card or entry into a raffle for prize worth about $200 if they complete screening.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational text messaging
Description: Intervention sends up to 4 motivational messages by text or email to Alaska Native men who are active patients and due for colorectal cancer screening. Incentive arms include promise of a $50 gift card or entry into a raffle for prize worth about $200 if they complete screening.
Study: NCT04673058

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation
Description: Intervention will be administered twice a week for 3 weeks. Each treatment session will be given in 20-minute sessions consisting of 10 minutes of manual examination and 10 minutes of manual treatment.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Manipulation
Description: The practitioner will primarily identify the areas where somatic dysfunction is detected and keep the application away from these areas. The patient will be positioned for treatment as in active therapy, but once in the lock position, a lower thrust will be given by releasing some back from the position.
Study: NCT05595876

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stent retriever thrombectomy
Description: The technique used should be in accordance with the device IFU (instructions for use). A large bore access guide catheter possible is mandatory. A suitable delivery microcatheter is navigated over a microwire across the occlusion. A control superselective angiogram may be used to document the extent of occlusion and thrombus. The stent is left in place according to the internal practice of each participating center before the withdrawal. Any CE (european compliance)-marked stent retriever device is then deployed across the occlusion. A contact aspiration large bore catheter can be used in association with the stent retriever. A minimum of 3 attempts with Stent retriever should be performed. A revascularization score will be recorded after each device attempt.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: contact aspiration thrombectomy
Description: A 0.021 to 0.027 inch inner lumen microcatheter with a 0.014 to 0.016 inch microwire inside is then introduced into a large-bore aspiration catheter and this construct is introduced into the long sheath as a unit. A large bore balloon guide catheter has to be placed into the cervical internal carotid artery. The microcatheter is then advanced close to the thrombus and the large-bore aspiration catheter is advanced as close to the proximal aspect of the thrombus as possible. A control angiogram may be used to document the extent of occlusion and thrombus. After a 3 min waiting period, the large-bore aspiration catheter is connected to a continuous aspiration from the dedicated aspiration pump while simultaneously advancing the aspiration catheter up to the face of the thrombus. Once thrombus will be close to the aspiration catheter, then the system will carefully removed as a unit under continuous aspiration.
Study: NCT05657769

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medwell Preventive Care Application
Description: Regular diabetes treatment with additional Medwell application and wearable device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Records
Description: Regular diabetes treatment only with a diary card to record daily activities manually.
Study: NCT05516329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A single dose of 7±1 mCi (259±37 MBq) IV injection of 18F-Thretide
Description: The patients will be intravenously injected with 18F-Thretide and undergo PET/CT scan at 60\~120 min after the injection.
Study: NCT05241652

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory Muscle Training with an intensity of 50% MIP
Description: Patients received IMT exercise program at a 50% MIP intensity for 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inspiratory Muscle Training with an intensity of 10% MIP
Description: Patients received IMT exercise program at a 10% MIP intensity for 12 weeks
Study: NCT05501925

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlideSheath Slender® and conventional arterial sheath
Description: Using the GlideSheath Slender® with the outside diameter 2.46mm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional arterial sheath
Description: Placement of 6 French conventional Sheath (TERUMO, Introducer II )
Study: NCT06503198

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual care
Description: Through Cloud DX, intervention group participants will receive:~Remote Automated Monitoring: measurement of: blood pressure, heart rate, respiratory rate, oxygen saturation, temperature and weight.~Frailty-tailored daily symptom survey: The recovery survey consists of questions related to infection, bleeding, pain, appetite, dehydration, appetite, syncope and falls.~The tablet will prompt the participant to complete a Katz Index of Independence in Activities of Daily Living (IADL) survey. The FAM-CAM survey will also be pushed by Cloud DX to be completed.~Virtual RN assessment: a virtual RN assessment will be scheduled at a minimum of every 2 days for the first 7 days. The virtual RN will also perform the 4AT Delirium Assessment.~Medications: the virtual RN will undertake medication review and reconciliation. In addition, they will provide counselling regarding analgesic support and monitor for drug interactions.
Study: NCT04888611

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus GSC-DCV
Description: Prior to scheduled surgery, patients need to receive Camrelizumab IV (3mg/kg, up to 200mg). After surgery, patients receive Camrelizumab IV (3mg/kg, up to 200mg) and GSC-DCV IH every 3 weeks in the absence of disease progression or unacceptable toxicity.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Camrelizumab plus Placebo
Description: Prior to scheduled surgery, patients need to receive Camrelizumab IV (3mg/kg, up to 200mg). After surgery, patients receive Camrelizumab IV (3mg/kg, up to 200mg) and Placebo IH every 3 weeks in the absence of disease progression or unacceptable toxicity.
Study: NCT04800380

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Edpuzzle interactive videos
Description: The effectiveness of the Edpuzzle application will be evaluated in developing the metric and drug dose calculation skills of first year nursing students.
Study: NCT03973814

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermax Blood Warmer
Description: Patients will be their own controls: Prior to-, during-, and after Thermax blood warming.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermax Blood Warmer
Description: Patients will be their own controls: Prior to-, during-, and after Thermax blood warming.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermax Blood Warmer
Description: Patients will be their own controls: Prior to-, during-, and after Thermax blood warming.
Study: NCT05437887

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fucoidan
Description: All patients consumed fucoidan.
Study: NCT04733820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Description: Drug: Paclitaxel or docetaxel + Cisplatin or carboplatin Paclitaxel 135-175mg/m2 over 3 hours or docetaxel 70-75 mg/m2， 30min ＋ Cisplatin 75-80mg/m2 or carboplatin AUC = 5, repeat per 21 days.
Study: NCT06041555

Intervention type: OTHER
Intervention: 3 MRI sequences (T2*, IVIM and Multi Echo-Gradient), without injection, are performed
Description: Generate 3D maps of intra-tumoral hypoxia and characterize their evolution during treatment thanks to the establishment of a prospective database of MRI sequences
Study: NCT05134909

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Customized contact lens
Description: The customized lenses are designed to correct the eye's optical aberrations.
Study: NCT05152212

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LVGN7409
Description: Route of administration is IV infusion, and the frequency of administration is once every 3 weeks(Q3W). One cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.
Study: NCT05300022

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TeKnO T1D: Parents
Description: app-delivered curriculum to provide psychoeducational education surrounding diabetes technology use
Study: NCT04638452

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Video & movements recording
Description: Video recording of face, body movements and physiological parameters (heart rate, conductance using a wireless watch) of the participants during the blood test

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires
Description: Passing self and hetero questionnaires of emotion felt and perceived.
Study: NCT03850795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HC-1119
Description: oral once daily 80 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: oral once daily 160 mg
Study: NCT06451575

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood collection
Description: Blood collection

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood collection
Description: Blood collection
Study: NCT05015660

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left bundle branch pacing lead (Select Secure 3830 lead)
Description: Implantation of a left bundle branch pacing lead via sheath, to perform selective or non-selective pacing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Right ventricular active fixation lead
Description: Active fixation lead (standard)
Study: NCT04543357

Intervention type: OTHER
Intervention: Blood Draw
Description: Blood Samples for NAb and ADA to AAV9
Study: NCT05327608

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short-Term Fasting
Description: Undergo intermittent fasting
Study: NCT05516056

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERAS clinical pathway
Description: Prospective evaluation of the clinical results of ERAS implementation in the first 50 patients undergoing ERAS for cholecystectomy in CHUK, Rwanda
Study: NCT03763396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole (KCZ)
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole (KCZ)
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole (PCZ)
Description: Delayed Release Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole (PCZ)
Description: Delayed Release Oral Tablet
Study: NCT05238961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]DPA-714
Description: Investigational PET Tracer \[18F\]DPA-714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]DPA-714
Description: Investigational PET Tracer \[18F\]DPA-714
Study: NCT03609866

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rapid thoracic compression technique
Description: in the expiratory time of the ventilation set, it will be applied a rapid thoracic compression

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: inferior limb passive mobilization
Description: it will be performed a passive mobilization technique on the patient
Study: NCT06216756

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: osteochondral transplant on the femoral condyle
Description: Patients who have a symptomatic full-thickness cartilage lesion (Grade 3 or 4) on the femoral condyle, in a mechanically stable knee, or is being mechanically stabilized in the same procedure, between 2.0-8.0 cm2 in size, and cystic changes requiring osseous repair present in less than or equal to 12 mm of subchondral bone will undergo a osteochondral transplant by removing the damaged cartilage and replacing that cartilage with a cryopreserved osteochondral allograft core.
Study: NCT05917925

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: COLLAGEN (COL)
Description: The collagen-based supplement will be ingested every day for 12 weeks at the same time.
Study: NCT05067270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Citrate
Description: Administered SC infusion.
Study: NCT05917925

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO (PLA)
Description: The placebo will be ingested every day for 12 weeks at the same time.
Study: NCT04915495

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: LuViva Advanced Cervical Scan
Description: Multimodal hyperspectral device
Study: NCT04786353

Intervention type: OTHER
Intervention: LongCOVIDkidsDK
Description: Exposure: To be identified as an exposure for the current study, children from 0-18 years with at least one positive SARS-CoV-2 test will be identified from COVID-19 data from January 2020 until the last updated version. To be able to identify the parents who will receive the questionnaires we will also need CPR-data on the children's parents.
Study: NCT04921215

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Morning bright light
Description: All participants will receive phase advancing morning bright light.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Morning bright light
Description: All participants will receive phase advancing morning bright light.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Morning bright light
Description: All participants will receive phase advancing morning bright light.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Morning bright light
Description: All participants will receive phase advancing morning bright light.
Study: NCT05412706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Patients will receive Niraparib 200-300 mg orally as an individualized weight and platelet-based, flat-fixed, continuous daily dose.~Niraparib will be administered orally once daily in 28-day cycles.
Study: NCT05779891

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Traction Straight Leg Raise Technique
Description: The individuals in the Group A will be receive hot pack at lower back for 10 minutes followed by ultrasound at 1.5w/cm2 for 10 minutes. The treatment will be preceded by Mulligan straight leg raise technique . Three repetitions of Mulligan's Traction Straight Leg Raise will be done with 7 seconds hold and 5 seconds relax time. The total treatment protocol will be 30 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Slump Stretching
Description: The individuals in the Group B will be receive hot pack at lower back for 10 minutes followed by ultrasound at 1.5w/cm2 for 10 minutes. The treatment will be preceded by Slump Stretching technique. Five repetitions of Slump stretching technique will be done with 30 seconds hold and 5 seconds relax time. The total treatment protocol will be 30 minutes
Study: NCT05278390

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic CT scan
Description: Automated quantitative analysis of altered pulmonary volume
Study: NCT06454864

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guidelines-based healthy eating
Description: One-on-one phone/virtual counselling from a registered dietitian to change dietary habits to be in line with Canada's Food Guide.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guidelines-based physical activity
Description: Through a combination of exercise trainer-led in-person and virtual sessions, as well as counselling for independent aerobic exercise, participants will be guided to achieve 150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guidelines-based physical activity
Description: Through a combination of exercise trainer-led in-person and virtual sessions, as well as counselling for independent aerobic exercise, participants will be guided to achieve 150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Stretching exercise
Description: Twice weekly virtual instructor-led whole-body stretching.
Study: NCT06231043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac/Tramadol
Description: Arm Drug1 :Diclofenac 75 mg (3 ml) IM injection by doctor, then followed by normal saline 20 ml IV injection (equal to Tramadol diluted) by nurse.~Arm Drug2 :Normal saline 3 ml IM injection by doctor (equal to Diclofenac 75 mg), then followed by Tramadol 50 mg (1 ml) dilute with normal saline 19 ml (total 20 ml )IV injection by nurse.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac/Tramadol
Description: Arm Drug1 :Diclofenac 75 mg (3 ml) IM injection by doctor, then followed by normal saline 20 ml IV injection (equal to Tramadol diluted) by nurse.~Arm Drug2 :Normal saline 3 ml IM injection by doctor (equal to Diclofenac 75 mg), then followed by Tramadol 50 mg (1 ml) dilute with normal saline 19 ml (total 20 ml )IV injection by nurse.
Study: NCT06401980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Darolutamide will be supplied in bottles as 300 mg film-coated tablets for oral intake

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: * Docetaxel~* Cabazitaxel~* LuPSMA~* Radium 223~* Olaparib, in case of BRCA1 or 2 mutated or HRR deficient tumors~The standard of care is chosen by the local investigator and respecting the country specific approvals.
Study: NCT05159414

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse Electrical Stimulation
Description: Pulse Electrical Stimulation Patients wear our clinical trial device 30mins once a day for 16weeks.
Study: NCT05841940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]HLX208
Description: Carbon-14 labeled HLX208
Study: NCT05067270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Citrate
Description: Administered SC infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Citrate
Description: Administered SC infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Citrate
Description: Administered SC infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil
Description: Administered SC infusion.